The Influence of Influenza and Pneumococcal Vaccines on Community-Acquired Pneumonia (CAP) Outcomes Among Elderly Patients

Current Infectious Disease Reports

Volumn 17, Issue 12, 2015, Pages

  Gubbins, Paul O ^a   Li, Chenghui ^b  

^a UNIVERSITY OF MISSOURI KANSAS CITY   (United States)

^b UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

Author keywords

13 valent pneumococcal conjugate vaccine; 23 valent pneumococcal polysaccharide vaccine; Community acquired pneumonia outcomes; Elderly; Seasonal influenza vaccine

Indexed keywords

INFLUENZA VACCINE; PNEUMOCOCCUS VACCINE;

COMMUNITY ACQUIRED PNEUMONIA; DRUG EFFICACY; DRUG USE; ELDERLY CARE; HUMAN; INFECTION PREVENTION; INFECTION RISK; INFLUENZA; INFLUENZA VACCINATION; LENGTH OF STAY; MORTALITY; OUTCOME ASSESSMENT; PNEUMOCOCCAL INFECTION; REVIEW; VACCINATION;

EID: 84943371913     PISSN: 15233847     EISSN: 15343146     Source Type: Journal    
DOI: 10.1007/s11908-015-0505-6     Document Type: Review

References (30)

1. Centers for Disease Control and Prevention 2013 “Deaths: final data for 2013.” http://www.cdc.gov/nchs/data/nvsr/nvsr64/nvsr64_02.pdf accessed July 23, 2015.
2. Park H, Adeyemi AO, Rascati KL. Direct medical costs and utilization of health care services to treat pneumonia in the United States: an analysis of the 2007–2011 medical expenditure survey. Clin Ther. 2015;37:1466–76.
3. Weil-Oliviera C, Gaillat J. Can the success of pneumococcal conjugate vaccines for the prevention of pneumococcal diseases in children be extrapolated to adults? Vaccine. 2014;32:2022–6.
4. Jain S, Self WH, Wunderink RG, et al. Community-acquired pneumonia requiring hospitalization among U.S. adults. N Engl J Med. 2015;373:415–27.
5. Fry AM, Kim IK, Reed C, et al. Modeling the effect of different vaccine effectiveness estimates on the number of vaccine-prevented influenza-associated hospitalizations in older adults. Clin Infect Dis. 2014;59:406–9.
6. Campigotto A, Mubareka S. Influenza-associated bacterial pneumonia; managing and controlling infection on two fronts. Expert Rev Anti Infect Ther. 2015;13:55–68.
7. Christopolou I, Roose K, Ibañez LI, Saelens X. Influenza vaccines to control influenza-associated bacterial infection: where do we stand? Expert Rev Vaccines. 2015;14:55–67.
8. McCullers JA. The co-pathogenesis of influenza viruses with bacteria in the lung. Nat Rev Microbiol. 2014;12:252–62.
9. Siegel SJ, Roche AM, Weiser JN. Influenza promotes pneumococcal growth during coinfection by providing host sialylated substrates as a nutrient source. Cell Host Microbe. 2014;16:55–67.
10. Smith SB, Ruhnke GW, Weiss CH, Waterer GW, Wunderink RG. Trends in pathogens among patients hospitalized for pneumonia from 1993 to 2011. JAMA Intern Med. 2014;174:1837–9.
11. Liapikou A, Polverino E, Cilloniz C, et al. Worldwide perspective of nursing home-acquired pneumonia compared to community-acquired pneumonia. Respir Care. 2014;59:1078–85.
12. Drijkoningen JJC, Rohde GGU. Pneumococcal infection in adults: burden of disease. Clin Microbiol Infect. 2014;20 Suppl 5:45–51.
13. Curcio D, Cane' A, Isturiz R. Redefining risk categories for pneumococcal disease in adults: critical analysis of the evidence. Int J Infect Dis. 2015;37:30–5.
14. Shea KM, Edelsberg J, Weycker D, et al. Rates of pneumococcal disease in adults with chronic medical conditions. Open Forum Infect Dis 2014. doi: 10.1093/ofid/ofu024. eCollection 2014
15. Bonten MJM, Huijts SM, Bolkenbaas M, et al. Polysaccharide conjugate vaccine against pneumococcal pneumonia in adults. N Engl J Med. 2015;372:1114–25.
16. Weinberger DM, Shapiro ED. Pneumococcal conjugate vaccines for adults reasons for optimism and for caution. Hum Vaccine Immunother. 2014;10:1334–6.
17. Tomczyk S, Bennett NM, Stoecker C, et al. Use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine among adults aged ≥ 65 years: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep. 2014;63:822–5.
18. Fedson DS. Preventing non bacteremic pneumococcal pneumonia in older adults. Hum Vaccine Immunother. 2014;10:1322–30.
19. Klugman KP. A tale of 2 pneumococcal vaccines. Clin Infect Dis. 2014;58:925–7.
20. Payeras A, Villoslada A, Garau M, Salvador MN, Gallegos MC. Evolution of pneumococcal infections in adult patients during a four-year period after vaccination of a pediatric population with 13-valent pneumococcal conjugate vaccine. Int J Infect Dis. 2015;33:22–7.
21. Moore MR, Link-Gelles R, Schaffner W, et al. Effect of use of 13-valent pneumococcal conjugate vaccine in children on invasive pneumococcal disease in children and adults in the USA: analysis of multisite, population-based surveillance. Lancet Infect Dis. 2015;15:301–9.
22. Ochoa-Gondar O, Vila-Corcoles A, Rodriguez-Blanco T, et al. Effectiveness of the 23-valent pneumococcal polysaccharide vaccine against community-acquired pneumonia in the general population aged ≥60 years: 3 years of follow-up in the CAPAMIS study. Clin Infect Dis. 2014;58(7):909–17.
23. Leventer-Roberts M, Feldman BS, Brufman I, et al. Effectiveness of 23-valent pneumococcal polysaccharide vaccine against invasive disease and hospital-treated pneumonia among people aged ≥65 years: a retrospective case-control study. Clin Infect Dis. 2015;60:1472–80.
24. Wiemken TL, Carrico RM, Klein SL, et al. The effectiveness of the polysaccharide pneumococcal vaccine for the prevention of hospitalizations due to Streptococcus pneumoniae community-acquired pneumonia in the elderly differs between the sexes: results from the Community-Acquired Pneumonia Organization (CAPO) international cohort study. Vaccine. 2014;32:2198–203.
25. Mina MJ, Klugman KP. The role of influenza in the severity and transmission of respiratory bacterial disease. Lancet Respir Med. 2014;2:750–63.
26. Darvishan M, Gefenaite G, Turner RM, et al. After adjusting for bias in meta-analysis seasonal vaccine remains effective in community dwelling elderly. J Clin Epidemiol. 2014;67:734–44.
27. McLean HQ, Meece JK, Belongia EA. Influenza vaccination and risk of hospitalization among adults with laboratory confirmed influenza illness. Vaccine. 2014;32:453–7.
28. Song JY, Lee JS, Wie SH, et al. Prospective cohort study on the effectiveness of influenza and pneumococcal vaccines in preventing pneumonia development and hospitalization. Clin Vaccine Immunol. 2015;22:229–34.
29. Li C, Gubbins PO, Chen GJ. Prior pneumococcal vaccination and influenza vaccinations and in-hospitalization outcomes for community-acquired pneumonia in the elderly veterans. J Hosp Med. 2015;10:287–93.
30. Grijalva CG, Nuorti JP, Arbogast PG, et al. Decline in pneumonia admissions after routine childhood immunisation with pneumococcal conjugate vaccine in the USA: a time-series analysis. Lancet. 2007;7(369(9568)):1179–86.